TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness and Cost-effectiveness of Two Multi-component Interventions to Improve the Health Outcomes in People With Type 2 Diabetes Mellitus
Brief Summary: Objective:

* To improve health outcomes of patients with type 2 diabetes mellitus (T2DM) by influencing disease self-management through lifestyle modification and by helping primary care professionals to improve health care provided to patients.
* To assess the effectiveness and cost-effectiveness of two complex interventions (education and behavioural modification, independently and conjointly, for primary health care teams (PHCT) and patients and their relatives) to improve the health results in people with T2DM.

Methodology:

Design: Randomized clinical trial. Setting: Basic healthcare district in Canary Islands. Spain. Subjects: Patients with T2DM, 18-65 years old, without complications. Main measures: HbA1c, rate of patients with properly controlled T2DM. Sample: 2328 patients, 582 per arm. Intervention: G1: Interventions on the patients: Educational and habit modification group program. G2: Intervention on the PHCT: a) Educative intervention to improve the knowledge about the disease and their abilities; b) Computer-based clinical decision support system; c) Feedback of results. G3: Interventions on the patients and the PHCT. G4: Control group. Patients receive only the usual care.


Options:
A: Intervention Type: DEVICE; Name: online health information journal; Assigned to Arm(s): N/A
B: Arm Label: Basal Insulin Initiation Strategy; Type: EXPERIMENTAL; Interventions: Other: Basal Insulin Initiation Strategy | Arm Label: Usual Practice; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Basal Insulin Initiation Strategy; Assigned to Arm(s): Basal Insulin Initiation Strategy
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Daily physical activity, pedometer and counseling | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Daily physical activity, pedometer and counseling; Assigned to Arm(s): 1
D: Arm Label: Intervention to Patients; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention to patients, Other: Usual care | Arm Label: Intervention to healthcare Professionals; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention to professionals, Other: Usual care | Arm Label: Mixed Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention to patients, Behavioral: Intervention to professionals, Other: Usual care | Arm Label: Control; Type: OTHER; Interventions: Other: Usual care | Intervention Type: BEHAVIORAL; Name: Intervention to patients; Assigned to Arm(s): Intervention to Patients, Mixed Intervention | Intervention Type: BEHAVIORAL; Name: Intervention to professionals; Assigned to Arm(s): Intervention to healthcare Professionals, Mixed Intervention | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Control, Intervention to Patients, Intervention to healthcare Professionals, Mixed Intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Solitaire™ FR With the Intention For Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME) Clinical Trial
Brief Summary: The primary study objective is to determine if subjects experiencing an acute ischemic stroke due to large vessel occlusion, treated with combined IV t-PA and Solitaire Revascularization Device within 6 hours of symptom onset have less stroke-related neurological disability (mRS) than those subjects treated with IV t-PA alone


Options:
A: Arm Label: Penumbra System with Separator 3D; Type: EXPERIMENTAL; Interventions: Device: Penumbra System with Separator 3D | Arm Label: Penumbra System alone; Type: ACTIVE_COMPARATOR; Interventions: Device: Penumbra System alone | Intervention Type: DEVICE; Name: Penumbra System with Separator 3D; Assigned to Arm(s): Penumbra System with Separator 3D | Intervention Type: DEVICE; Name: Penumbra System alone; Assigned to Arm(s): Penumbra System alone
B: Arm Label: ADAPT; Type: EXPERIMENTAL; Interventions: Procedure: direct aspiration procedure | Arm Label: Stent Retriever; Type: ACTIVE_COMPARATOR; Interventions: Procedure: stent retriever procedure | Intervention Type: PROCEDURE; Name: direct aspiration procedure; Assigned to Arm(s): ADAPT | Intervention Type: PROCEDURE; Name: stent retriever procedure; Assigned to Arm(s): Stent Retriever
C: Arm Label: Combined use of contact aspiration and stent retriever; Type: EXPERIMENTAL; Interventions: Combination Product: Combined contact aspiration/Stent Retriever Technique | Arm Label: Stent retriever mechanical thrombectomy alone; Type: ACTIVE_COMPARATOR; Interventions: Device: Stent retriever technique | Intervention Type: COMBINATION_PRODUCT; Name: Combined contact aspiration/Stent Retriever Technique; Assigned to Arm(s): Combined use of contact aspiration and stent retriever | Intervention Type: DEVICE; Name: Stent retriever technique; Assigned to Arm(s): Stent retriever mechanical thrombectomy alone
D: Arm Label: IV t-PA with Solitaire™ revascularization device; Type: EXPERIMENTAL; Interventions: Device: Solitaire revascularization device | Arm Label: IV t-PA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous (IV) recombinant human tissue plasminogen activator (rtPA) | Intervention Type: DRUG; Name: Intravenous (IV) recombinant human tissue plasminogen activator (rtPA); Assigned to Arm(s): IV t-PA | Intervention Type: DEVICE; Name: Solitaire revascularization device; Assigned to Arm(s): IV t-PA with Solitaire™ revascularization device

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Solitaire™ FR With the Intention For Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME) Clinical Trial
Brief Summary: The primary study objective is to determine if subjects experiencing an acute ischemic stroke due to large vessel occlusion, treated with combined IV t-PA and Solitaire Revascularization Device within 6 hours of symptom onset have less stroke-related neurological disability (mRS) than those subjects treated with IV t-PA alone


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: IV tpa (Alteplase) vs IA tpa (Alteplase) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV tpa (Alteplase) vs IA tpa (Alteplase) | Intervention Type: DRUG; Name: IV tpa (Alteplase) vs IA tpa (Alteplase); Assigned to Arm(s): 1, 2
B: Arm Label: Trevo Thrombectomy Procedure; Type: EXPERIMENTAL; Interventions: Device: Trevo Thrombectomy Procedure, Other: Medical Management | Arm Label: Medical Management; Type: ACTIVE_COMPARATOR; Interventions: Other: Medical Management | Intervention Type: DEVICE; Name: Trevo Thrombectomy Procedure; Assigned to Arm(s): Trevo Thrombectomy Procedure | Intervention Type: OTHER; Name: Medical Management; Assigned to Arm(s): Medical Management, Trevo Thrombectomy Procedure
C: Arm Label: Best standard treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Best standard treatment | Arm Label: Mechanical thrombectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: mechanical thrombectomy | Intervention Type: PROCEDURE; Name: mechanical thrombectomy; Assigned to Arm(s): Mechanical thrombectomy | Intervention Type: DRUG; Name: Best standard treatment; Assigned to Arm(s): Best standard treatment
D: Arm Label: IV t-PA with Solitaire™ revascularization device; Type: EXPERIMENTAL; Interventions: Device: Solitaire revascularization device | Arm Label: IV t-PA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous (IV) recombinant human tissue plasminogen activator (rtPA) | Intervention Type: DRUG; Name: Intravenous (IV) recombinant human tissue plasminogen activator (rtPA); Assigned to Arm(s): IV t-PA | Intervention Type: DEVICE; Name: Solitaire revascularization device; Assigned to Arm(s): IV t-PA with Solitaire™ revascularization device

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Solitaire™ FR With the Intention For Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME) Clinical Trial
Brief Summary: The primary study objective is to determine if subjects experiencing an acute ischemic stroke due to large vessel occlusion, treated with combined IV t-PA and Solitaire Revascularization Device within 6 hours of symptom onset have less stroke-related neurological disability (mRS) than those subjects treated with IV t-PA alone


Options:
A: Arm Label: IV t-PA with Solitaire™ revascularization device; Type: EXPERIMENTAL; Interventions: Device: Solitaire revascularization device | Arm Label: IV t-PA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous (IV) recombinant human tissue plasminogen activator (rtPA) | Intervention Type: DRUG; Name: Intravenous (IV) recombinant human tissue plasminogen activator (rtPA); Assigned to Arm(s): IV t-PA | Intervention Type: DEVICE; Name: Solitaire revascularization device; Assigned to Arm(s): IV t-PA with Solitaire™ revascularization device
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Endovascular thrombectomy/thrombolysis; Type: EXPERIMENTAL; Interventions: Procedure: Endovascular thrombectomy/thrombolysis | Intervention Type: PROCEDURE; Name: Endovascular thrombectomy/thrombolysis; Assigned to Arm(s): Endovascular thrombectomy/thrombolysis
C: Arm Label: IA thrombolysis; Type: EXPERIMENTAL; Interventions: Other: Alteplase IA and/or mechanical thrombolysis | Arm Label: IV rtPA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Alteplase IV | Intervention Type: OTHER; Name: Alteplase IA and/or mechanical thrombolysis; Assigned to Arm(s): IA thrombolysis | Intervention Type: DRUG; Name: Alteplase IV; Assigned to Arm(s): IV rtPA
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: local interarterial recombinant tissue plasminogen activator | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravenous (IV) rt-PA | Intervention Type: DRUG; Name: local interarterial recombinant tissue plasminogen activator; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: intravenous (IV) rt-PA; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Neuromuscular Electrical Stimulation as an Adjunct to Exercise Training in Stable COPD
Brief Summary: Skeletal muscle dysfunction impairs exercise capacity, quality of life and prognosis in chronic obstructive pulmonary disease (COPD). The purpose of this prospective randomized controlled study was to evaluate effects of Neuromuscular electrical stimulation (NMES) plus quadriceps muscle training (NMES group) and sham NMES plus quadriceps muscle training (control group) on muscle function, exercise capacity, health related quality of life, activities of daily living, and self-efficacy in patients with COPD who are eligible and able to participate in endurance training.


Options:
A: Arm Label: ES; Type: ACTIVE_COMPARATOR; Interventions: Device: Electrostimulation | Arm Label: Sham ES; Type: PLACEBO_COMPARATOR; Interventions: Device: Sham stimulation | Intervention Type: DEVICE; Name: Electrostimulation; Assigned to Arm(s): ES | Intervention Type: DEVICE; Name: Sham stimulation; Assigned to Arm(s): Sham ES
B: Arm Label: Functional electrical stimulation; Type: EXPERIMENTAL; Interventions: Procedure: Functional electrical stimulation | Arm Label: Medium-frequency alternating current; Type: EXPERIMENTAL; Interventions: Procedure: Medium-frequency alternating current | Arm Label: Burst-modulated alternating current; Type: EXPERIMENTAL; Interventions: Procedure: Burst-modulated alternating current | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Placebo | Intervention Type: PROCEDURE; Name: Medium-frequency alternating current; Assigned to Arm(s): Medium-frequency alternating current | Intervention Type: PROCEDURE; Name: Burst-modulated alternating current; Assigned to Arm(s): Burst-modulated alternating current | Intervention Type: PROCEDURE; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: PROCEDURE; Name: Functional electrical stimulation; Assigned to Arm(s): Functional electrical stimulation
C: Arm Label: NMES group; Type: EXPERIMENTAL; Interventions: Other: Neuromuscular electrical stimulation, Other: Endurance training, Other: Quadriceps strength training | Arm Label: Control group; Type: SHAM_COMPARATOR; Interventions: Other: Endurance training, Other: Quadriceps strength training | Intervention Type: OTHER; Name: Neuromuscular electrical stimulation; Assigned to Arm(s): NMES group | Intervention Type: OTHER; Name: Endurance training; Assigned to Arm(s): Control group, NMES group | Intervention Type: OTHER; Name: Quadriceps strength training; Assigned to Arm(s): Control group, NMES group
D: Arm Label: No Treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Electrical Stimulation; Type: EXPERIMENTAL; Interventions: Device: Electrical Stimulation | Intervention Type: DEVICE; Name: Electrical Stimulation; Assigned to Arm(s): Electrical Stimulation

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Neuromuscular Electrical Stimulation as an Adjunct to Exercise Training in Stable COPD
Brief Summary: Skeletal muscle dysfunction impairs exercise capacity, quality of life and prognosis in chronic obstructive pulmonary disease (COPD). The purpose of this prospective randomized controlled study was to evaluate effects of Neuromuscular electrical stimulation (NMES) plus quadriceps muscle training (NMES group) and sham NMES plus quadriceps muscle training (control group) on muscle function, exercise capacity, health related quality of life, activities of daily living, and self-efficacy in patients with COPD who are eligible and able to participate in endurance training.


Options:
A: Intervention Type: DEVICE; Name: Neuromuscular Electrical stimulator (Cefar rehab 4 pro); Assigned to Arm(s): N/A
B: Arm Label: One single arm group; Type: EXPERIMENTAL; Interventions: Device: FES-cycling, Device: Classic cycloergometer | Intervention Type: DEVICE; Name: FES-cycling; Assigned to Arm(s): One single arm group | Intervention Type: DEVICE; Name: Classic cycloergometer; Assigned to Arm(s): One single arm group
C: Arm Label: Functional electrical stimulation; Type: EXPERIMENTAL; Interventions: Procedure: Functional electrical stimulation | Arm Label: Medium-frequency alternating current; Type: EXPERIMENTAL; Interventions: Procedure: Medium-frequency alternating current | Arm Label: Burst-modulated alternating current; Type: EXPERIMENTAL; Interventions: Procedure: Burst-modulated alternating current | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Placebo | Intervention Type: PROCEDURE; Name: Medium-frequency alternating current; Assigned to Arm(s): Medium-frequency alternating current | Intervention Type: PROCEDURE; Name: Burst-modulated alternating current; Assigned to Arm(s): Burst-modulated alternating current | Intervention Type: PROCEDURE; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: PROCEDURE; Name: Functional electrical stimulation; Assigned to Arm(s): Functional electrical stimulation
D: Arm Label: NMES group; Type: EXPERIMENTAL; Interventions: Other: Neuromuscular electrical stimulation, Other: Endurance training, Other: Quadriceps strength training | Arm Label: Control group; Type: SHAM_COMPARATOR; Interventions: Other: Endurance training, Other: Quadriceps strength training | Intervention Type: OTHER; Name: Neuromuscular electrical stimulation; Assigned to Arm(s): NMES group | Intervention Type: OTHER; Name: Endurance training; Assigned to Arm(s): Control group, NMES group | Intervention Type: OTHER; Name: Quadriceps strength training; Assigned to Arm(s): Control group, NMES group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tranexamic Acid for the Treatment of Gastrointestinal Haemorrhage: an International Randomised, Double Blind Placebo Controlled Trial
Brief Summary: Severe bleeding in the digestive system is a common symptom of many diseases. Each year, about 50,000 people end up in British hospitals because of this problem and about 5,000 of them die. The most common cause of this bleeding is stomach ulcers. In sub-Saharan Africa, schistosomiasis (parasitic worms) is responsible for about 130,000 deaths from stomach bleeding each year. From previous research in other bleeding conditions such as surgery and trauma, we know that a drug called tranexamic acid can reduce bleeding and save lives. We now want to do the HALT-IT trial to see if giving tranexamic acid can save lives and if there are any complications in people with severe bleeding from the digestive system.


Options:
A: Arm Label: Group A: RiaSTAP; Type: EXPERIMENTAL; Interventions: Drug: Human fibrinogen concentrate | Arm Label: Group B: apheresis platelets; Type: ACTIVE_COMPARATOR; Interventions: Other: apheresis platelets | Intervention Type: DRUG; Name: Human fibrinogen concentrate; Assigned to Arm(s): Group A: RiaSTAP | Intervention Type: OTHER; Name: apheresis platelets; Assigned to Arm(s): Group B: apheresis platelets
B: Arm Label: Fibrinogen Concentrate; Type: EXPERIMENTAL; Interventions: Drug: Fibrinogen Concentrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Isotonic Saline | Intervention Type: DRUG; Name: Fibrinogen Concentrate; Assigned to Arm(s): Fibrinogen Concentrate | Intervention Type: DRUG; Name: Isotonic Saline; Assigned to Arm(s): Placebo
C: Arm Label: Tranexamic acid; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic Acid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): Tranexamic acid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Fibrinogen Concentrate (Human); Type: EXPERIMENTAL; Interventions: Biological: Fibrinogen Concentrate (Human) (FCH) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Fibrinogen Concentrate (Human) (FCH); Assigned to Arm(s): Fibrinogen Concentrate (Human) | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tranexamic Acid for the Treatment of Gastrointestinal Haemorrhage: an International Randomised, Double Blind Placebo Controlled Trial
Brief Summary: Severe bleeding in the digestive system is a common symptom of many diseases. Each year, about 50,000 people end up in British hospitals because of this problem and about 5,000 of them die. The most common cause of this bleeding is stomach ulcers. In sub-Saharan Africa, schistosomiasis (parasitic worms) is responsible for about 130,000 deaths from stomach bleeding each year. From previous research in other bleeding conditions such as surgery and trauma, we know that a drug called tranexamic acid can reduce bleeding and save lives. We now want to do the HALT-IT trial to see if giving tranexamic acid can save lives and if there are any complications in people with severe bleeding from the digestive system.


Options:
A: Arm Label: Tranexamic acid; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic Acid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): Tranexamic acid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Tranexamic Acid Group; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic Acid | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebos | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): Tranexamic Acid Group | Intervention Type: DRUG; Name: Placebos; Assigned to Arm(s): Placebo group
C: Arm Label: RIRS; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Retrograde intrarenal surgery | Arm Label: PCNL; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Percutaneous nephrolithotomy | Intervention Type: PROCEDURE; Name: Percutaneous nephrolithotomy; Assigned to Arm(s): PCNL | Intervention Type: PROCEDURE; Name: Retrograde intrarenal surgery; Assigned to Arm(s): RIRS
D: Arm Label: PCNL Group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: PCNL | Arm Label: mini-PCNL Group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: mini-PCNL | Arm Label: RIRS Group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: RIRS | Intervention Type: PROCEDURE; Name: PCNL; Assigned to Arm(s): PCNL Group | Intervention Type: PROCEDURE; Name: mini-PCNL; Assigned to Arm(s): mini-PCNL Group | Intervention Type: PROCEDURE; Name: RIRS; Assigned to Arm(s): RIRS Group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Random Controlled, Double-Blind Clinical Trial: Remote Ischemic Preconditioning and Cerebral Small Vessel Disease
Brief Summary: The hypothesis of this study is that remote ischemic preconditioning (RIPC) might have a beneficial effect on outcomes of cerebral small vessel disease (CSV).


Options:
A: Arm Label: Trevo Thrombectomy Procedure; Type: EXPERIMENTAL; Interventions: Device: Trevo Thrombectomy Procedure, Other: Medical Management | Arm Label: Medical Management; Type: ACTIVE_COMPARATOR; Interventions: Other: Medical Management | Intervention Type: DEVICE; Name: Trevo Thrombectomy Procedure; Assigned to Arm(s): Trevo Thrombectomy Procedure | Intervention Type: OTHER; Name: Medical Management; Assigned to Arm(s): Medical Management, Trevo Thrombectomy Procedure
B: Arm Label: remote ischemic preconditioning; Type: EXPERIMENTAL; Interventions: Procedure: remote ischemic preconditioning | Arm Label: placebo remote ischemic preconditioning; Type: SHAM_COMPARATOR; Interventions: Procedure: sham remote ischemic preconditioning | Intervention Type: PROCEDURE; Name: remote ischemic preconditioning; Assigned to Arm(s): remote ischemic preconditioning | Intervention Type: PROCEDURE; Name: sham remote ischemic preconditioning; Assigned to Arm(s): placebo remote ischemic preconditioning
C: Intervention Type: PROCEDURE; Name: remote ischemic preconditioning; Assigned to Arm(s): N/A
D: Arm Label: Thrombolysis + Remote perconditioning; Type: EXPERIMENTAL; Interventions: Procedure: Thrombolysis + remote perconditioning | Arm Label: Thrombolysis; Type: ACTIVE_COMPARATOR; Interventions: Drug: Actilyse | Intervention Type: DRUG; Name: Actilyse; Assigned to Arm(s): Thrombolysis | Intervention Type: PROCEDURE; Name: Thrombolysis + remote perconditioning; Assigned to Arm(s): Thrombolysis + Remote perconditioning

Answer: B